Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | WNT3A | P56704 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.49 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.49 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | LDLR | P01130 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17512402 | 0.82 | LMNA (0.52) | ALDH1A1LMNAKMT2AKDM4EMAPT | |
| SCHEMBL16097992 | 0.82 | HDAC1 (0.61) | MCHR1HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL17512365 | 0.81 | LMNA (0.51) | ALDH1A1LMNAKMT2AKDM4EMAPT | |
| SCHEMBL16097389 | 0.80 | WNT3A (0.63) | MCHR1ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL16097123 | 0.80 | MCHR1 (0.56) | MCHR1HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL16129628 | 0.79 | WNT3A (0.62) | MCHR1ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL16099209 | 0.79 | WNT3A (0.59) | MCHR1ALDH1A1LMNAKMT2AKDM4E | |
| SCHEMBL16097798 | 0.79 | WNT3A (0.61) | MCHR1ALDH1A1KMT2AMAPTHSD17B10 | |
| SCHEMBL16097768 | 0.79 | WNT3A (0.61) | MCHR1ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL16098030 | 0.79 | WNT3A (0.64) | MCHR1ALDH1A1KMT2AMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | claimed |
| EP-2976343-A2 | SUBSTITUTED N-BIPHENYL-3-ACETYLAMINO-BENZAMIDES AND N-[3-(ACETYLAMINO)PHENYL]-BIPHENYL-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | claimed |
| WO-2014147182-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | claimed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| WO-2014147182-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052898-A1 | NOVEL COMPOUNDS | AADAC, NAT1, CCNA1 | MCHR1 4601/4885HDAC1 95/4885HDAC8 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.